Chinese Journal of Clinical Oncology

, Volume 2, Issue 1, pp 469–472 | Cite as

Clinical characteristics and treatment of malignant granuloma

  • Chongjin Feng
  • Junbing Guo
  • Yong Chen
Original Articles



To analyse the clinical characteristics of malignant granuloma (MG) and evaluate its treatment.


From March 1985 to May 1998, 101 cases of malignant granuloma were treated with radiation (RT) alone or radiotherapy followed by chemotherapy or chemotherapy followed by radiotherapy. For chemotherapy, a CCNU, COMP (CTX, VCR, MTX, PDN) or CHOP (CTX, ADM, VCR, PDN) regimen was given. Radiation was directed through the anterior field of the nose mainly for nasal and paranasal sinus malignant granuloma, and through the faciocervical field for malignant granuloma of Walderyer’s ring or for patients with cervical lymphadenectasis. Total dose was 45–65 Gy over 5–6 weeks.


The overall 3—year, 5—year and 10—year survival rates were 78.2%, 56.1% and 39.7% respectively. The 5—year survival rate was: RT group 60.3%, RT + CHOP or CHOP + RT group 64.7% (P >0.05), RT + CCNU group 40%, and RT + COMP group 33.3%. The 5—year survival rates of patients with one involved focus and more than 2 involved foci were 75.6% (34/45) and 39.3% (22/56) (P<0.001 ). The 5—year survival rates of patients with or without body symptoms were 39.6% (18/48) and 67.9%(36/53) (P< 0.05). The 5—year survival rate of the 50–60 Gy group and the <50Gy group were 60.1% (40/66) and 20% (1/5) (P <0.05). The local and regional recurrence rate was 20.8% (21/101).


Radiotherapy alone should be the treatment of choice for patients with one site involvement and without body symptoms. Radiation fields should be large enough to include the potentially involved sites. The recommended dose is 50 –60 Gy over 5–6 weeks. It is suggested that patients with more than 2 foci involvement and those with body symptoms should receive the combination therapy.


malignant granuloma radiotherapy chemotherapy 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Liu WP, Li GD, Xu SL. Pathomorphological and immunohistochemical study of midline malignant reticulosis. Chin J pathol. 1991; 20:103–105.Google Scholar
  2. 2.
    Feng CJ, Ding XQ, Chen XH. A clinicopathologic and immunohistochemical study of malignant granuloma. Acad J SUMS. 1999; 20:76–77.Google Scholar
  3. 3.
    Wang GB, Liu C, Zhao B, et al. CT, MRI and pathology study of malignant granuloma. Chin J MIT. 2001; 17: 632–634.Google Scholar
  4. 4.
    Armitage JO, Greer JP, Levine AM, et al. Peripheral T cell lymphoma. Cancer. 1989; 63: 158–163.PubMedCrossRefGoogle Scholar
  5. 5.
    Li JX, Liu YH, Xue XH. Midline peripheral T —cell lymphoma —A disease entity recognized anew. Chin J Oncol. 1990; 12:206–208.Google Scholar
  6. 6.
    Stewart JP. Progressive lethal granulomatous ulceration of the nose. J laryng. 1933; 48:657–701.Google Scholar
  7. 7.
    Gu ZP, Song ZE, Wang DC. The long term treatment result of malignant granuloma treated with radiotherapy. Chin J Radia Oncol. 1996; 5:171–173.Google Scholar
  8. 8.
    Zhou CH, Wang XY, Wang XY. Radiotherapy of malignant granuloma. Chin Oncol. 1999; 9:61.Google Scholar

Copyright information

© Chinese Anti-Cancer Association and Springer 2003

Authors and Affiliations

  • Chongjin Feng
    • 1
  • Junbing Guo
    • 1
  • Yong Chen
    • 2
  1. 1.Department of Stomatology, First Affiliated HospitalSun Yat-sen University of Medical SciencesGuangzhouChina
  2. 2.Department of Radiation Therapy, Tumor HospitalSun Yat-sen University of Medical SciencesGuangzhouChina

Personalised recommendations